Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (USRLD: Vivelle-Dot® Transdermal System).
Estradiol Transdermal System is indicated to treat moderate to severe symptoms of menopause which includes feelings of warmth in the face, neck and chest or sudden strong feelings of heat, hot flushes and vaginal dryness in women. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, India.
The group now has 336 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 411.30 as compared to the previous close of Rs. 409.45. The total number of shares traded during the day was 19464 in over 652 trades.
The stock hit an intraday high of Rs. 414.80 and intraday low of 408.25. The net turnover during the day was Rs. 8019907.00.
(*as of 30th September 2022)